Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation

Blood

Volumn 117, Issue 14, 2011, Pages 3921-3928

  Di Ianni, Mauro ^a,b   Falzetti, Franca ^a   Carotti, Alessandra ^a   Terenzi, Adelmo ^a   Castellino, Flora ^c   Bonifacio, Elisabetta ^a   Del Papa, Beatrice ^a   Zei, Tiziana ^a   Iacucci Ostini, Roberta ^a   Cecchini, Debora ^a   Aloisi, Teresa ^a   Perruccio, Katia ^a   Ruggeri, Loredana ^a   Balucani, Chiara ^a   Pierini, Antonio ^a   Sportoletti, Paolo ^a   Aristei, Cynthia ^a   Falini, Brunangelo ^a   Reisner, Yair ^d   Velardi, Andrea ^a   Aversa, Franco ^a   Martelli, Massimo F ^a   more..

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c Novartis Vaccines and Diagnostic   (Italy)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN;

ADOPTIVE TRANSFER; ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; PROPHYLAXIS; REGULATORY T LYMPHOCYTE; RISK FACTOR;

EID: 79953809817     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-311894     Document Type: Article

References (24)

1. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998; 339(17):1186-1193. (Pubitemid 28482127)
2. Aversa F, Terenzi A, Tabilio A, et al. Full haplotypemismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005; 23(15):3447-3454.
3. Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med. 1995;1(12):1268-1273.
4. Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol. Today. 1995; 16(9):437-440.
5. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84(11):3948-3955.
6. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009;10(5):440-442.
7. Perruccio K, Topini F, Tosti A, et al. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2008;40(1):76-83. (Pubitemid 350192305)
8. Amrolia PJ, Muccioli-Casadei G, Huls H et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006; 108(6):1797-1808. (Pubitemid 44394986)
9. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versushost disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389-399. (Pubitemid 34875667)
10. Nguyen VH, Shashidhar S, Chang Ds, et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood. 2008;111(2):945-953.
11. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493-3499. (Pubitemid 34534513)
12. Trenado A, Charlotte F, Fisson S, et al. Recipienttype specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graftversus- host disease while maintaining graftversus- leukemia. J Clin Inv. 2003;112(11):1688-1696. (Pubitemid 38063726)
13. Di Ianni M, Del Papa B, Cecchini D, et al. Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applications. Clin Exp Immunol. 2009;156(2):246-253.
14. Nguyen VH, Zeiser R, daSilva DL, et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graftversus-host disease following allogeneic transplantation. Blood. 2007;109(6):2649-2656. (Pubitemid 46425916)
15. Eiraku N, Hingorani R, Ijichi S, et al. Clonal expansion within CD4+ and CD8+ T cell subsets in human T lymphotropic virus type I-infected individuals. J Immunol. 1998;161(12):6674-6680. (Pubitemid 28562209)
16. Gorski J, Piatek T, Yassai M, Gorski J, Maslanka K. Improvements in repertoire analysis by CDR3 size spectratyping. Ann N Y Acad Sci. 1995;756: 99-102.
17. Wu Cj Chillemi A, Alyea EP, et al. Reconstitution of T-cell receptor repertoire diversity following T-cell-depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000;95(1):352-359. (Pubitemid 30017264)
18. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106(13):4397-4406. (Pubitemid 41775954)
19. Fischer A, Landais P, Friedrich W, et al. European experience of bone marrow transplantation for severe combined immunedeficiency. Lancet. 1990;336(8719):850-854. (Pubitemid 20311334)
20. Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34(+) progenitors cells from HLAmismatched parental donors in children. Bone Marrow Transpl. 2001;27(8):777-783. (Pubitemid 32496409)
21. Craddock CF. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. Bone Marrow Transpl. 2008;41(5):415-423. (Pubitemid 351386707)
22. Arcese W, Rocha V, Labopin M, et al. Unrelated cord blood transplants in adults with hematologic malignancies. Haematologica. 2006;91(2):223-230.
23. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graftversus-tumor activity while inhibiting graft-versushost disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150. (Pubitemid 37173698)
24. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100. (Pubitemid 34229476)